Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bruker (BRKR) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Bruker (BRKR) over the last 17 years, with Q3 2025 value amounting to $293.1 million.

  • Bruker's Cash & Equivalents rose 9790.68% to $293.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $293.1 million, marking a year-over-year increase of 9790.68%. This contributed to the annual value of $183.4 million for FY2024, which is 6244.11% down from last year.
  • Per Bruker's latest filing, its Cash & Equivalents stood at $293.1 million for Q3 2025, which was up 9790.68% from $92.0 million recorded in Q2 2025.
  • Over the past 5 years, Bruker's Cash & Equivalents peaked at $1.1 billion during Q4 2021, and registered a low of $92.0 million during Q2 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $573.0 million (2021), whereas its average is $483.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 7047.67% in 2024, then surged by 9790.68% in 2025.
  • Over the past 5 years, Bruker's Cash & Equivalents (Quarter) stood at $1.1 billion in 2021, then crashed by 39.57% to $645.5 million in 2022, then fell by 24.35% to $488.3 million in 2023, then crashed by 62.44% to $183.4 million in 2024, then surged by 59.81% to $293.1 million in 2025.
  • Its Cash & Equivalents stands at $293.1 million for Q3 2025, versus $92.0 million for Q2 2025 and $184.2 million for Q1 2025.